Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-011 in Metastatic Uveal Melanoma
NCT02363283Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2015
- Primary completion
- Jul 2018
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of glembatumumab vedotin in Uveal melanoma (UM), sponsored by National Cancer Institute. Started Sep 2015; status: completed.
02
Drugs
glembatumumab vedotin
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT02363283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02363283.